表现为孤立性淋巴结复发的卵巢癌的临床与分子特征
本研究比较49例孤立性淋巴结复发卵巢癌与49例匹配的结外复发卵巢癌,发现孤立性淋巴结复发组复发后生存和总生存均显著延长(多因素分析HR分别为0.52和0.51),且诊断标本中CD3+和CD8+ T细胞浸润显著更高,而BRCA1/2突变和CCNE1拷贝数增加频率无显著差异。
要点
- 孤立性淋巴结复发卵巢癌复发后生存和总生存均优于结外复发(多因素分析HR分别为0.52和0.51)。
- 孤立性淋巴结复发组诊断标本CD3+和CD8+ T细胞浸润显著高于结外复发组(P=.001和P=.009)。
- 两组BRCA1/2突变和CCNE1拷贝数增加频率无显著差异(P=.865和P=.900)。
核心结论
- 孤立性淋巴结复发卵巢癌是结局优于结外复发的独特临床实体。
- 孤立性淋巴结复发组BRCA1/2突变或CCNE1增益未见明显富集或缺失,提示这些已知预后基因组亚型未显著改变孤立性淋巴结复发倾向。
- 孤立性淋巴结复发患者诊断肿瘤标本CD3+和CD8+细胞浸润更高,提示T细胞群对肿瘤的参与更强,可能促成其更惰性的病程。
研究设计与样本
- 从Edinburgh卵巢癌数据库识别49例孤立性淋巴结复发卵巢癌患者,并按疾病分期、组织学亚型和分级、手术减瘤后残留病变范围及诊断时年龄匹配49例结外复发病例。
- 比较两队列的临床病理因素和生存数据。
- 对诊断时肿瘤材料进行基于panel的高通量测序基因组表征,并用CD3+和CD8+细胞免疫组化评估肿瘤浸润T细胞负荷。
主要发现
- 多因素分析显示孤立性淋巴结复发组复发后生存和总生存均显著长于结外复发组(HRmulti=0.52 [0.33-0.84]和0.51 [0.31-0.84])。
- 后续出现孤立性淋巴结复发的高级别浆液性卵巢癌诊断标本CD3+和CD8+细胞浸润显著高于结外复发病例(P=.001和P=.009,Bonferroni校正后P=.003和P=.019)。
- 孤立性淋巴结复发高级别浆液性卵巢癌与结外复发对应病例相比,BRCA1/2突变或CCNE1拷贝数增益未见明显富集或缺失(24.4% vs 19.4%和18.2% vs 22.6%,P=.865和P=.900)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Disease relapse is the primary cause of death from ovarian carcinoma. Isolated lymph node relapse is a rare pattern of ovarian carcinoma recurrence, with a reported median postrelapse survival of 2.5 to 4 years. To date, investigations have not compared isolated lymph node relapse ovarian carcinoma directly to a matched extranodal relapse cohort or performed molecular characterization of cases that subsequently experience isolated lymph node relapse. OBJECTIVE: Here we seek to compare the clinical outcome, tumor-infiltrating lymphocyte burden, and frequency of known prognostic genomic events in isolated lymph node relapse ovarian carcinoma vs extranodal relapse ovarian carcinoma. STUDY DESIGN: Forty-nine isolated lymph node relapse ovarian carcinoma patients were identified and matched to 49 extranodal relapse cases using the Edinburgh Ovarian Cancer Database, from which the clinical data for identified patients were retrieved. Matching criteria were disease stage, histologic subtype and grade, extent of residual disease following surgical debulking, and age at diagnosis. Clinicopathologic factors and survival data were compared between the isolated lymph node relapse and extranodal relapse cohorts. Genomic characterization of tumor material from diagnosis was performed using panel-based high-throughput sequencing and tumor-infiltrating T cell burden was assessed using immunohistochemistry for CD3+ and CD8+ cells. RESULTS: Isolated lymph node relapse cases demonstrated significantly prolonged postrelapse survival and overall survival vs extranodal relapse upon multivariable analysis (HRmulti = 0.52 [0.33-0.84] and 0.51 [0.31-0.84]). Diagnostic specimens from high-grade serous ovarian carcinomas that subsequently displayed isolated lymph node relapse harbored significantly greater CD3+ and CD8+ cell infiltration compared to extranodal relapse cases (P = .001 and P = .009, Bonferroni-adjusted P = .003 and P = .019). Isolated lymph node relapse high-grade serous ovarian carcinoma cases did not show marked enrichment or depletion of cases with BRCA1/2 mutation or CCNE1 copy number gain when compared to their extranodal relapse counterparts (24.4% vs 19.4% and 18.2% vs 22.6%, P = .865 and P = .900). CONCLUSION: Isolated lymph node relapse ovarian carcinoma represents a distinct clinical entity with favorable outcome compared to extranodal relapse. There was no clear enrichment or depletion of BRCA1/2 mutation or CCNE1 gain in the isolated lymph node relapse ovarian carcinoma cohort compared with extranodal relapse cases, suggesting that these known prognostic genomically defined subtypes of disease do not display markedly altered propensity for isolated lymph node relapse. Diagnostic tumor material from isolated lymph node relapse patients demonstrated greater CD3+ and CD8+ cell infiltration, indicating stronger tumor engagement by T cell populations, which may contribute to the more indolent disease course of isolated lymph node relapse.
引用
- Hollis RL, Carmichael J, Meynert AM, et al. Clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse. Am J Obstet Gynecol. 2019. PMID: 31055034. doi:10.1016/j.ajog.2019.04.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。